Published in Medical Letter on the CDC and FDA, February 24th, 2008
"The priority focus of HGS continues to be the rapid commercialization of our late-stage compounds - Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus, and ABthrax(TM) for inhalation anthrax. We also have an exciting mid- stage pipeline led by our oncology program," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA